دورية أكاديمية
أعرض في EDS

MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.

التفاصيل البيبلوغرافية
العنوان: MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.
المؤلفون: Musa J; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute for Pathology of the LMU Munich, Munich, Germany., Aynaud MM; INSERM Unit 830 'Genetics and Biology of Cancers', Institut Curie Research Center, Paris, France., Mirabeau O; INSERM Unit 830 'Genetics and Biology of Cancers', Institut Curie Research Center, Paris, France., Delattre O; INSERM Unit 830 'Genetics and Biology of Cancers', Institut Curie Research Center, Paris, France., Grünewald TG; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute for Pathology of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
المصدر: Cell death & disease [Cell Death Dis] 2017 Jun 22; Vol. 8 (6), pp. e2895. Date of Electronic Publication: 2017 Jun 22.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group
مواضيع طبية MeSH: Cell Differentiation*, Carcinogenesis/*metabolism , Carcinogenesis/*pathology , Trans-Activators/*metabolism, Animals ; Cell Cycle ; Cell Proliferation ; Cell Survival ; Humans
مستخلص: Limitless cell proliferation, evasion from apoptosis, dedifferentiation, metastatic spread and therapy resistance: all these properties of a cancer cell contribute to its malignant phenotype and affect patient outcome. MYBL2 (alias B-Myb) is a transcription factor of the MYB transcription factor family and a physiological regulator of cell cycle progression, cell survival and cell differentiation. When deregulated in cancer cells, MYBL2 mediates the deregulation of these properties. In fact, MYBL2 is overexpressed and associated with poor patient outcome in numerous cancer entities. MYBL2 and players of its downstream transcriptional network can be used as prognostic and/or predictive biomarkers as well as potential therapeutic targets to offer less toxic and more specific anti-cancer therapies in future. In this review, we summarize current knowledge on the physiological roles of MYBL2 and highlight the impact of its deregulation on cancer initiation and progression.
References: Am J Cancer Res. 2015 Mar 15;5(4):1542-52. (PMID: 26101717)
Gene. 2005 May 23;351:171-80. (PMID: 15922873)
Oncogene. 1992 Jun;7(6):1233-40. (PMID: 1594249)
Biochim Biophys Acta. 2007 Apr;1772(4):392-401. (PMID: 17229557)
Cancer Res. 2009 May 1;69(9):4073-80. (PMID: 19383908)
Blood. 1992 May 15;79(10):2708-16. (PMID: 1586718)
Nat Rev Drug Discov. 2015 Feb;14(2):130-46. (PMID: 25633797)
EMBO J. 1994 Feb 15;13(4):871-8. (PMID: 8112300)
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7438-43. (PMID: 12032301)
EMBO J. 2002 Feb 15;21(4):675-84. (PMID: 11847115)
J Biol Chem. 1999 Dec 17;274(51):36741-9. (PMID: 10593981)
Brain Res. 2001 Feb 16;892(1):203-7. (PMID: 11172765)
Oncotarget. 2015 Dec 8;6(39):41402-17. (PMID: 26595675)
Nucleic Acids Res. 2016 Jan 8;44(1):164-74. (PMID: 26384566)
Nat Rev Cancer. 2008 Jul;8(7):523-34. (PMID: 18574464)
Br J Cancer. 2015 Sep 1;113(5):693-8. (PMID: 26180922)
Immunology. 2005 Jan;114(1):25-36. (PMID: 15606792)
Clin Cancer Res. 2008 Mar 15;14(6):1639-48. (PMID: 18347165)
J Cell Sci. 2006 Apr 15;119(Pt 8):1483-93. (PMID: 16551698)
J Mol Med (Berl). 2007 Mar;85(3):293-304. (PMID: 17143621)
Development. 2002 Jan;129(2):347-59. (PMID: 11807028)
Blood. 1994 Apr 1;83(7):1778-90. (PMID: 8142646)
J Biol Chem. 2003 Nov 7;278(45):44255-64. (PMID: 12947099)
Cancer Res. 1999 May 15;59(10):2451-6. (PMID: 10344757)
Arch Dermatol Res. 2014 May;306(4):375-84. (PMID: 24515894)
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):532-6. (PMID: 9012818)
Oncogene. 2000 Jan 20;19(3):373-9. (PMID: 10656684)
Cell Cycle. 2012 Dec 15;11(24):4661-72. (PMID: 23187802)
J Neurosci. 2004 Oct 6;24(40):8720-5. (PMID: 15470138)
J Exp Clin Cancer Res. 2013 Dec 01;32:98. (PMID: 24289849)
Oncotarget. 2017 Feb 14;8(7):11160-11172. (PMID: 28061449)
PLoS One. 2012;7(8):e42350. (PMID: 22936984)
Cell Cycle. 2014;13(20):3249-59. (PMID: 25485505)
Clin Cancer Res. 2000 May;6(5):1833-9. (PMID: 10815905)
J Pathol. 2014 Apr;232(5):522-33. (PMID: 24374933)
EMBO J. 2007 Jan 10;26(1):144-57. (PMID: 17159899)
Cells Tissues Organs. 2008;188(1-2):31-45. (PMID: 18303244)
J Neurosci. 2007 Jan 24;27(4):893-900. (PMID: 17251431)
Oncogene. 2009 Apr 16;28(15):1737-47. (PMID: 19252525)
Oncogene. 2007 Nov 29;26(54):7535-43. (PMID: 17563750)
Leuk Res. 2013 Dec;37(12):1690-6. (PMID: 24199710)
Oncogene. 2014 Jul 31;33(31):4039-49. (PMID: 24141769)
Oncogene. 2000 Jan 13;19(2):298-306. (PMID: 10645009)
Biol Reprod. 2014 Nov;91(5):113. (PMID: 25273528)
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3122-7. (PMID: 24516162)
J Gen Virol. 2011 Nov;92(Pt 11):2620-7. (PMID: 21813705)
EMBO J. 1994 Dec 15;13(24):5994-6005. (PMID: 7813437)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Mol Cell Biol. 2008 Sep;28(17 ):5162-71. (PMID: 18573889)
Stem Cells. 2010 Oct;28(10 ):1751-9. (PMID: 20715180)
J Biol Chem. 2000 Jul 14;275(28):21055-60. (PMID: 10770937)
Clin Pharmacol Ther. 2017 Jan;101(1):89-98. (PMID: 27806433)
Oncogene. 2001 Mar 22;20(12):1425-34. (PMID: 11313886)
Cancer Cell Int. 2016 Jun 23;16:49. (PMID: 27340370)
Hepatology. 2011 Apr;53(4):1226-36. (PMID: 21480327)
Clin Cancer Res. 2011 May 1;17 (9):2712-24. (PMID: 21367750)
Nucleic Acids Res. 2012 Feb;40(4):1561-78. (PMID: 22064854)
Blood Cells Mol Dis. 2003 Sep-Oct;31(2):192-200. (PMID: 12972026)
Oncogene. 2017 Jan 5;36(1):110-121. (PMID: 27212033)
Nature. 1979 Oct 11;281(5731):452-5. (PMID: 226888)
Cancer Res. 2002 Dec 1;62(23):6803-7. (PMID: 12460888)
Oncogene. 1999 Nov 25;18(50):7016-25. (PMID: 10597302)
Nucleic Acids Res. 1988 Dec 9;16(23):11075-89. (PMID: 3060855)
J Biol Chem. 2002 Feb 8;277(6):4088-97. (PMID: 11733503)
Biomark Cancer. 2016 Mar 13;8:25-42. (PMID: 26997872)
Oncogene. 2002 Nov 14;21(52):7923-32. (PMID: 12439743)
J Biol Chem. 1996 Nov 15;271(46):28738-40. (PMID: 8910512)
Int J Oncol. 1993 Mar;2(3):419-23. (PMID: 21573571)
EMBO J. 2004 Nov 24;23(23):4615-26. (PMID: 15510213)
Oncotarget. 2010 Aug;1(4):278-88. (PMID: 21304178)
Oncogene. 2003 May 15;22(19):2932-41. (PMID: 12771944)
Cancer Res. 2000 Sep 15;60(18):5027-30. (PMID: 11016623)
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5819-27. (PMID: 25337223)
Oncotarget. 2017 Feb 28;8(9):16052-16074. (PMID: 28030802)
Oncogene. 2005 Nov 3;24(48):7127-34. (PMID: 16170378)
Int J Cancer. 2010 Mar 15;126(6):1390-402. (PMID: 19821490)
Am J Hum Genet. 2016 Apr 7;98 (4):709-27. (PMID: 27058444)
Cell. 1991 May 17;65(4):677-89. (PMID: 1709592)
Blood Cells Mol Dis. 2007 Nov-Dec;39(3):263-71. (PMID: 17588787)
Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40. (PMID: 17667954)
Mol Cell Biol. 2002 Jun;22(11):3663-73. (PMID: 11997503)
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13194-9. (PMID: 16150706)
Aging Cell. 2014 Oct;13(5):773-9. (PMID: 24981831)
Cell Mol Life Sci. 2011 Mar;68(5):893-901. (PMID: 20734103)
J Cell Physiol. 2011 Mar;226(3):785-91. (PMID: 20857481)
PLoS One. 2008 Jun 25;3(6):e2478. (PMID: 18575582)
J Cell Biochem. 1997 Sep 1;66(3):309-21. (PMID: 9257188)
Blood. 1996 Mar 1;87(5):1900-11. (PMID: 8634438)
Cell Death Differ. 1998 May;5(5):401-7. (PMID: 10200489)
Dev Biol. 2012 Dec 1;372(1):88-102. (PMID: 22960039)
Nat Rev Cancer. 2013 Aug;13(8):585-95. (PMID: 23842645)
Genetics. 2005 Jan;169(1):215-29. (PMID: 15489525)
Nat Rev Cancer. 2016 Apr;16(4):251-65. (PMID: 27009395)
Nature. 1997 Apr 17;386(6626):713-7. (PMID: 9109487)
J Biol Chem. 2014 Jun 27;289(26):18202-13. (PMID: 24828495)
EMBO J. 2008 Jul 9;27(13):1852-62. (PMID: 18548008)
Autophagy. 2015;11(7):1081-98. (PMID: 26060891)
Cancer Res. 1999 Jul 15;59(14):3365-8. (PMID: 10416595)
Genes Dev. 1998 Mar 15;12(6):831-43. (PMID: 9512517)
J Biol Chem. 2005 Apr 22;280(16):15628-34. (PMID: 15618219)
Med Oncol. 2015 Jan;32(1):412. (PMID: 25502082)
Oncogene. 1999 Oct 14;18(42):5821-30. (PMID: 10523863)
Cancer Res. 1995 Feb 1;55(3):501-4. (PMID: 7834617)
Nat Commun. 2015 Jan 05;6:5800. (PMID: 25557911)
Breast Cancer Res Treat. 2011 Dec;130(3):905-16. (PMID: 21630024)
Oncogene. 2001 Dec 13;20(57):8167-74. (PMID: 11781832)
Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G508-18. (PMID: 21737779)
Oncogene. 2004 Feb 19;23 (7):1392-404. (PMID: 14973551)
Oncogene. 1996 Jan 18;12(2):355-63. (PMID: 8570212)
Blood. 1995 Sep 1;86(5):1873-80. (PMID: 7655015)
Oncogene. 2000 Jun 15;19(26):2986-95. (PMID: 10871850)
J Biol Chem. 2003 Mar 14;278(11):9655-62. (PMID: 12645566)
J Biol Chem. 1995 Apr 14;270(15):8540-5. (PMID: 7721753)
Oncogene. 1999 Feb 11;18(6):1333-9. (PMID: 10022815)
Genes Dev. 2012 Mar 1;26(5):474-89. (PMID: 22391450)
Nat Cell Biol. 2008 Sep;10 (9):1076-82. (PMID: 19160488)
Curr Opin Cell Biol. 2016 Dec;43:7-13. (PMID: 27371787)
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10079-83. (PMID: 7937841)
Oncogene. 1996 Sep 19;13(6):1161-8. (PMID: 8808690)
Pharmacol Res. 2016 May;107:249-75. (PMID: 26995305)
J Biol Chem. 2000 Apr 7;275(14):10692-6. (PMID: 10744766)
J Biol Chem. 2011 Mar 4;286(9):7439-56. (PMID: 21148321)
Neuron. 2001 Nov 8;32(3):425-38. (PMID: 11709154)
J Biol Chem. 1997 Mar 7;272(10):6278-84. (PMID: 9045645)
Genes Dev. 1993 Jun;7(6):1097-109. (PMID: 8504932)
Cancer Res. 2011 Aug 15;71(16):5370-3. (PMID: 21828240)
Cell Cycle. 2008 Sep 1;7(17):2643-6. (PMID: 18719391)
J Biol Chem. 1999 Oct 1;274(40):28067-70. (PMID: 10497154)
المشرفين على المادة: 0 (Trans-Activators)
تواريخ الأحداث: Date Created: 20170623 Date Completed: 20180326 Latest Revision: 20220330
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5520903
DOI: 10.1038/cddis.2017.244
PMID: 28640249
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-4889
DOI:10.1038/cddis.2017.244